Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10335399rdf:typepubmed:Citationlld:pubmed
pubmed-article:10335399lifeskim:mentionsumls-concept:C0019704lld:lifeskim
pubmed-article:10335399lifeskim:mentionsumls-concept:C0524914lld:lifeskim
pubmed-article:10335399lifeskim:mentionsumls-concept:C0302350lld:lifeskim
pubmed-article:10335399lifeskim:mentionsumls-concept:C1550548lld:lifeskim
pubmed-article:10335399lifeskim:mentionsumls-concept:C1555714lld:lifeskim
pubmed-article:10335399lifeskim:mentionsumls-concept:C1705654lld:lifeskim
pubmed-article:10335399lifeskim:mentionsumls-concept:C1521840lld:lifeskim
pubmed-article:10335399pubmed:issue2lld:pubmed
pubmed-article:10335399pubmed:dateCreated1999-7-22lld:pubmed
pubmed-article:10335399pubmed:abstractTextAfter the identification of CD4 as the primary receptor for human immunodeficiency virus (HIV) type 1 entry into cells of the immune system, it soon became clear that CD4 alone was not sufficient to establish a productive infection. The search for the second receptors or co-receptors started over 10 years ago, and it was not until 1996 that G protein-coupled 7-transmembrane receptors, CXCR4 and CCR5 were finally identified as the co-receptors for HIV-1 entry. The 7-transmembrane receptor family is a familiar therapeutic target for a number of diseases, and therefore these recent findings represent an exciting opportunity for new therapeutic approaches to the treatment of HIV-1 infection.lld:pubmed
pubmed-article:10335399pubmed:languageenglld:pubmed
pubmed-article:10335399pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10335399pubmed:citationSubsetIMlld:pubmed
pubmed-article:10335399pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10335399pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10335399pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10335399pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10335399pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10335399pubmed:statusMEDLINElld:pubmed
pubmed-article:10335399pubmed:monthMarlld:pubmed
pubmed-article:10335399pubmed:issn0956-3202lld:pubmed
pubmed-article:10335399pubmed:authorpubmed-author:CammackNNlld:pubmed
pubmed-article:10335399pubmed:issnTypePrintlld:pubmed
pubmed-article:10335399pubmed:volume10lld:pubmed
pubmed-article:10335399pubmed:ownerNLMlld:pubmed
pubmed-article:10335399pubmed:authorsCompleteYlld:pubmed
pubmed-article:10335399pubmed:pagination53-62lld:pubmed
pubmed-article:10335399pubmed:dateRevised2005-11-16lld:pubmed
pubmed-article:10335399pubmed:meshHeadingpubmed-meshheading:10335399...lld:pubmed
pubmed-article:10335399pubmed:meshHeadingpubmed-meshheading:10335399...lld:pubmed
pubmed-article:10335399pubmed:meshHeadingpubmed-meshheading:10335399...lld:pubmed
pubmed-article:10335399pubmed:meshHeadingpubmed-meshheading:10335399...lld:pubmed
pubmed-article:10335399pubmed:meshHeadingpubmed-meshheading:10335399...lld:pubmed
pubmed-article:10335399pubmed:meshHeadingpubmed-meshheading:10335399...lld:pubmed
pubmed-article:10335399pubmed:meshHeadingpubmed-meshheading:10335399...lld:pubmed
pubmed-article:10335399pubmed:meshHeadingpubmed-meshheading:10335399...lld:pubmed
pubmed-article:10335399pubmed:year1999lld:pubmed
pubmed-article:10335399pubmed:articleTitleHuman immunodeficiency virus type 1 entry and chemokine receptors: a new therapeutic target.lld:pubmed
pubmed-article:10335399pubmed:affiliationDepartment of Virology, Roche Discovery Welwyn, Welwyn Garden City, UK.lld:pubmed
pubmed-article:10335399pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10335399pubmed:publicationTypeReviewlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10335399lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10335399lld:pubmed